DIA Logo
From Two Trials to One: Maximizing the Opportunity With Real-World Data

June 30, 2026 | 01:00-2:00PM ET

truvetalogo300dpi.jpeg (2)

 

 

WEBINAR OVERVIEW

The FDA’s acceptance of single pivotal trial pathways is reshaping how therapies reach patients, creating new opportunities to accelerate development while managing cost and risk. To succeed in this new one-trial paradigm, organizations must rethink how trials are designed and how evidence is generated. Real-world data is emerging as a critical enabler, informing smarter trial design, supporting external comparators, and extending evidence beyond traditional trial endpoints. In this webinar, we will explore how these approaches can be applied across the clinical lifecycle, including feasibility, enrollment, and post-market follow-up, along with key regulatory use cases. Join us to learn how leading organizations are modernizing clinical development to move faster, make more confident decisions, and deliver therapies to improve patient lives sooner.    

 

FEATURED TOPICS:

  • Improve trial design and enrollment with real-world data 
  • Support single-arm trials and regulatory submissions 
  • Generate longitudinal evidence for safety and effectiveness

 

Speakers

 

Johnathan Lancaster headshot 
 
Johnathan Lancster, MD, PhD 

Johnathan Lancaster, MD, PhD is President and Chief Scientific Officer at Truveta. Previously, Dr. Lancaster served as Senior Vice President and Head of Global Medical Affairs at Regeneron, Global Chief Medical Officer at Myriad Genetics, and spent more than a decade at Moffitt Cancer Center as a gynecologic oncologist, translational researcher, Chair of Women’s Oncology, and President of the Moffitt Medical Group.

A graduate of the University of Cambridge and Duke University, Dr. Lancaster is a pioneer in cancer genomics and personalized medicine, has authored over 100 peer-reviewed publications, and holds eight patents in cancer detection and therapeutics.

 
Esther Kim_Truveta (1) 
 
Esther Kim, PhD 

Esther Kim is the Senior Director, Research Services at Truveta, where she leads a multidisciplinary team that converts Truveta’s electronic health record data into rigorous, regulatory-grade evidence. With a passion for epidemiological methods, she oversees the full life cycle of research studies conducted with Truveta partners – designing protocols and statistical-analysis plans, and shepherding findings through peer-review and regulatory submission. 

Esther earned her PhD in epidemiology from the Johns Hopkins Bloomberg School of Public Health, specializing in cardiovascular disease research. She enjoys exploring and applying methods for estimating disease burden, risks of outcomes, and causal associations.